Lack of association between the CYP1A1 Ile462Val polymorphism and endometrial cancer risk: A meta-analysis

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 8, 2012, Pages 3717-3721

  Wang, Xi Wen ^a   Zhong, Tian Yu ^b   Xiong, Yun Hui ^c   Lin, Hai Bo ^a   Liu, Qing Yi ^a  

^a Birth Defects Prevention Research and Transformation Team   (China)

^b GANNAN MEDICAL UNIVERSITY   (China)

^c China   (China)

Author keywords

Cyp1a1; Endometrial cancer; Meta analysis; Polymorphism

Indexed keywords

EID: 84873642137     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.8.3717     Document Type: Article

References (33)

1. Ashton KA, Proietto A, Otton G, et al (2010). Polymorphisms in genes of the steroid hormone biosynthesis and metabolism pathways and endometrial cancer risk. Cancer Epidemiol, 34, 328-37.
2. Auersperg N, Edeson MI, Mok SC, et al (1998) The biology of ovarian cancer. Semin Oncol, 25, 281-304.
3. Barrena Medel NI, Bansal S, Miller DS, et al (2009). Pharmacotherapy of endometrial cancer. Expert Opin Pharmacother, 10, 1939-51.
4. Cochran WG (1954). The combination of estimates from different experiments. Biometrics, 10, 101-29.
5. Cosma G, Crofts F, Taioli E, et al (1993). Relationship between genotype and function of the human CYP1A1 gene. J Toxicol Environ Health, 40, 309-16.
6. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.
7. Doherty JA, Weiss NS, Freeman RJ, et al (2005). Genetic factors in catechol estrogen metabolism in relation to the risk of endometrial cancer.. Cancer Epidemiol Biomarkers Prev, 14, 357-66.
8. Drakoulis N, Cascorbi I, Brockmoller J, et al (1994) Polymorphism in the human CYP 1 A 1gene as susceptibility factors for lung cancer: exon-7 mutation (4889 A to G), and a T to C mutation in the 3'- flanking region. Clin Invest, 72, 240-8.
9. Egger M, Davey Smith G. Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34.
10. Elwood JM, Cole P, Rothman KJ, et al (1977). Epidemiology of endometrial cancer. J Natl Cancer Inst, 59, 1055-60.
11. Esinler I, Aktasy D, Alikasifogluy M, et al (2006). CYP1A1 gene polymorphism and risk of endometrial hyperplasia and endometrial carcinoma. Int J Gynecol Cancer, 16, 1407-11.
12. Esteller M, Garcia A, Martinez-Palones JM, et al (1997). Germ line polymorphisms in cytochrome-P450 1A1 (C4887 CYP1A1) and methylenetetrahydrofolate reductase (MTHFR) genes and endometrial cancer susceptibility. Carcinogenesis, 18, 2307-11.
13. Esteller M, Garcia A, Martinez-Palones JM, et al (1997). Susceptibility to endometrial cancer: influence of allelism at p53, glutathione S-transferase (GSTM1 and GSTT1) and cytochrome P-450 (CYP1A1) loci. Br J Cancer, 75, 1385-8.
14. Fader AN, Arriba LN, Frasure HE, et al (2009). Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship. Gynecol Oncol, 114, 121-7
15. Hayashi S, Watanabe J, Nakachi K, et al (1991). Genetic linkage of lung cancer-associated Msp1 polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P4501A1. J Biochem, 110, 407-11.
16. Herrington CS (2001). What we could do now: molecular pathology of gynaecological cancer. Mol Pathol, 54, 222-4.
17. Higgins JP, Thompson SE (2002). Quantifying heterogeneity in a metaanalysis. Stat Med, 21, 1539-58.
18. Hirata H, Hinoda Y, Okayama N, et al (2008). CYP1A1, SULT1A1, and SULT1E1 polymorphisms are risk factors for endometrial cancer susceptibility. Cancer, 112, 1964-73.
19. Kawajiri K, Nakachi K, Imai K, et al (1993). The CYP1A1 gene and cancer susceptibility. Crit Rev Oncol Hematol, 14, 77-7.
20. Key TJ, Pike MC (1988). The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer, 57, 205-12.
21. Kiyohara C, Hirohata T, Inutsuka S (1996). The relationship between aryl hydrocarbon hydroxylase and polymorphisms of the CYP1A1 gene. Jpn J Cancer Res, 87, 18-24.
22. La Vecchia C, Decarli A, Fasoli M, et al (1986). Nutrition and diet in the etiology of endometrial cancer. Cancer, 57, 1248-53.
23. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
24. Martucci CP, Fishman J (1993). P450 enzymes of estrogen metabolism. Pharmacol Ther, 57, 237-57.
25. McGrath M, Hankinson SE, De Vivo I (2007). Cytochrome P450 1A1, cigarette smoking, and risk of endometrial cancer (United States). Cancer Causes Control, 18, 1123-30.
26. Petersen DD, McKinney CE, Ikeya K, et al (1991). Human CYP1A1 gene: cosegregation of the enzyme inducibility phenotype and an RFLP. Am J Hum Genet, 48, 720-5.
27. Rebbeck TR, Troxel AB, Wang Y, et al (2006). Estrogen sulfation genes, hormone replacement therapy, and endometrial cancer risk. J Natl Cancer Inst, 98, 1311-20.
28. Schwarz D, Kisselev P, Schunck WH, et al (2000). Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity. Pharmacogenetics, 10, 519-30.
29. Seremak-Mrozikiewicz A, Drews K, Semczuk A, et al (2005). CYP1A1 alleles in female genital cancers in the Polish population. Eur J Obstet Gynecol Reprod Biol, 118, 246-50.
30. Sugawara T, Nomura E, Sagawa T, et al (2003). CYP1A1 polymorphism and risk of gynecological malignancy in Japan. Int J Gynecol Cancer, 13, 785-90.
31. Taioli E, Crofts F, Trachman J, et al (1995) Radical differences in CYP1A1 genotype and function. Toxicol Lett, 77, 357-62.
32. Zhang ZY, Fasco MJ, Huang L, et al (1996). Characterization of purified human recombinant cytochrome P4501A1-Ile462 and -Val462: assessment of a role for the rare allele in carcinogenesis. Cancer Res, 56, 3926-33.
33. Zintzaras E, Chatzoulis DZ, Karabatsas CH, et al (2005). The relationship between C677T methylenetetrahydrofolate reductase gene polymorphism and retinopathy in type 2 diabetes: a metaanalysis. J Hum Genet, 50, 267-75.